Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

× No keyword cloud information.

31 in total

1. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.

Authors: C J Gallagher; F Cairnduff; I E Smith
Journal: Eur J Cancer Clin Oncol Date: 1987-12

2. Medroxyprogesterone acetate in human serum.

Authors: M Mathrubutham; K Fotherby
Journal: J Steroid Biochem Date: 1981-08 Impact factor: 4.292

3. Progestin therapy of breast cancer: comparison of agents.

Authors: B A Stoll
Journal: Br Med J Date: 1967-08-05

4. Plasma concentrations of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects.

Authors: H Adlercreutz; P B Eriksen; M S Christensen
Journal: J Pharm Biomed Anal Date: 1983 Impact factor: 3.935

5. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.

Authors: F Cavalli; A Goldhirsch; F Jungi; G Martz; P Alberto
Journal: J Clin Oncol Date: 1984-05 Impact factor: 44.544

6. In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.

Authors: C Gupta; J Osterman; R Santen; C W Bardin
Journal: J Clin Endocrinol Metab Date: 1979-05 Impact factor: 5.958

7. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.

Authors: C M Camaggi; E Strocchi; B Costanti; P Beghelli; P Ferrari; F Pannuti
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

8. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors: H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

9. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.

Authors: V Tamassia; A Battaglia; F Ganzina; A M Isetta; G Sacchetti; F Cavalli; A Goldhirsch; K Brunner; G Bernardo; G Robustelli della Cuna
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

10. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.

Authors: G R Cuna; A Calciati; M R Strada; C Bumma; L Campio
Journal: Tumori Date: 1978-04-30